High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
about
Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas diseaseCharacterising the KMP-11 and HSP-70 recombinant antigens' humoral immune response profile in chagasic patients.Chromosome level assembly of the hybrid Trypanosoma cruzi genome.A search for Trypanosoma brucei rhodesiense diagnostic antigens by proteomic screening and targeted cloning.Ten years of Chagas disease research: Looking back to achievements, looking ahead to challengesChanges in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.Neglected parasitic infections in the United States: Chagas diseaseThe centennial of the discovery of Chagas disease: facing the current challengesTrypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina.Methodological advances in drug discovery for Chagas disease.Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease.Chagas disease and the london declaration on neglected tropical diseases.Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil.Diagnostic peptide discovery: prioritization of pathogen diagnostic markers using multiple features.Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review.Anti-Trypanosoma cruzi cross-reactive antibodies detected at high rate in non-exposed individuals living in non-endemic regions: seroprevalence and association to other viral serologiesMapping antigenic motifs in the trypomastigote small surface antigen from Trypanosoma cruzi.FC-TRIPLEX Chagas/Leish IgG1: a multiplexed flow cytometry method for differential serological diagnosis of chagas disease and leishmaniasis.Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives.Highly discordant serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used for diagnostic.Evaluation of in-house ELISA using Trypanosoma cruzi lysate and recombinant antigens for diagnosis of Chagas disease and discrimination of its clinical formsSequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.Detection of Trypanosoma cruzi infection in naturally infected dogs and cats using serological, parasitological and molecular methods.Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern ArgentinaFrequency of IFNγ-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection.Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review.Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell ResponsesA 12-mer repetitive antigenic epitope from Trypanosoma cruzi is a potential marker of therapeutic efficacy in chronic Chagas' disease.Performance levels of four Latin American laboratories for the serodiagnosis of Chagas disease in Mexican sera samples.An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors.Secondary Structure Determination of Peptides and Proteins After Immobilization.Characterization and Diagnostic Application of Trypanosoma cruzi Trypomastigote Excreted-Secreted Antigens Shed in Extracellular Vesicles Released from Infected Mammalian Cells.Towards High-throughput Immunomics for Infectious Diseases: Use of Next-generation Peptide Microarrays for Rapid Discovery and Mapping of Antigenic Determinants.The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects.Systematic reference sample generation for multiplexed serological assays.Secretome analysis of Trypanosoma cruzi by proteomics studies.Next-generation ELISA diagnostic assay for Chagas Disease based on the combination of short peptidic epitopes.
P2860
Q28083346-BD7401FA-792B-4A87-8F70-87AB724B1BB0Q30918385-517D8372-A6DF-49C4-A48E-F6BD7CCE8428Q33457699-3195C88F-0003-44BF-B978-457200FB791CQ33540186-D567F354-0747-466E-8B46-7EE21F948AB5Q33584473-E61EDFF3-D722-47FE-BDA3-E1BFB77A19D4Q33585491-B6C3F042-1A3F-4BB6-8A50-1FC56A6B144CQ33588466-12FE61D1-1499-43E3-BC24-CCD572C6F189Q33627688-1B932C66-50FE-43DB-A5AD-DC6CADB53C4BQ33798381-BDEF8BBD-AB75-4EE9-9690-02770DA3DBEFQ33945347-A6730FB3-3F53-427D-9964-F397138D1254Q33975717-A3FAD3B4-8464-4A29-A73E-47B33636CBA7Q34016698-F2F1B8A2-BA9F-4E1F-B3DA-4B7393054F91Q34315066-79C4CE49-7C89-450F-A4BF-704A7D4A3E7CQ34380196-26312CFA-0421-44C9-8F87-33612A1B4668Q34524979-FCFD49D2-5C2F-48D4-A371-2482F3DA8CC3Q34992879-7F682406-5685-4F08-872B-3FA27956A4F3Q34999205-47C1599A-4AAE-4D93-8EE8-EEAA09084D24Q35122764-81D06681-4A95-4DBC-8A2A-32B48522C6E2Q35431307-D2B34C45-D683-41DE-AC5C-E96895A06F87Q35810790-44097AB9-90CC-4054-B869-599AC2239D76Q36069974-9BC11445-0E21-4196-AE38-1D4781268FA8Q36149620-18B7DBCF-82AA-4CFC-A2D3-933ADC69AD24Q36526649-1AEF57FA-6AC5-4820-97D2-5E3A38478FC0Q36911045-07F5D2FC-6628-476D-A945-C16F8E0816E8Q37007518-07D0FA8D-88DD-4261-9356-4A425CB50EF3Q37535347-1745AA09-8E69-4FA1-967B-4CD458381F7BQ37717875-0257BB56-9A5C-46C8-8314-9747FC0A521DQ38195336-AF598F4E-AC53-41AC-9283-A24CF8727B85Q38256874-58022F97-0D61-4682-B404-624AB7DEB421Q38871286-9274167D-D753-45C2-93BF-D3EC16380B26Q39002789-14493146-A6B7-49D8-BD10-E79D9CF8A11AQ39194954-C63078A0-BBC4-438E-A10A-073D5E9F4FAFQ40057259-20F07AD8-BEF3-4567-A13E-8AD714B3DB5AQ40404869-6010F290-ECCF-4DE0-AD41-CEB0DFDB6606Q40409819-8CAE855E-00EC-4A52-B943-7C8DA9E1628DQ41001466-BBAFE68A-E78A-4E61-BCB9-971BC51F2CE2Q41665227-4C439F4B-2B8D-44ED-88A9-5CA923D9C03EQ41818454-BAA8615D-B0FD-4393-BEB2-2894E4E3B036Q42369579-467BD83D-AD5C-4433-85F5-64A48986E6D4Q47136773-680D8762-013C-43A4-B3DF-9B12C6D1BB3F
P2860
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@ast
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@en
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@nl
type
label
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@ast
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@en
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@nl
prefLabel
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@ast
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@en
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@nl
P2093
P2860
P3181
P1476
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection
@en
P2093
Becky Bundy
Courtney Boehlke
D Brent Weatherly
Gretchen Cooley
Matthew Haney
Miriam Postan
R Drew Etheridge
Susana Laucella
Todd Minning
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0000316
P407
P5008
P577
2008-10-08T00:00:00Z